StreetAlpha.app
Home › Stocks › IRD

Opus Genetics, Inc. (IRD)

Healthcare
$4.05
▲ +0.25%
LAST CLOSE · NOV 17

Opus Genetics develops gene therapies for inherited retinal diseases that can cause severe vision loss. It last closed at $4.05 on Nov 17, up 0.25% on the day. The average 12-month price target from 7 analysts is $15.43 (+281.0% from the last close), with a high of $20.00 and a low of $11.00. Analyst consensus is Strong Buy, based on the latest ratings from 7 firms (7 buy, 0 hold, 0 sell).

AI Auto Pilots
Is IRD in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$7.9M
−45.9% vs a year ago
Net income
−$136.7M
−1726.7% margin
EPS (diluted)
−$1.48
Operating margin
−777.7%
−$61.5M operating income
Valuation
Market cap
$391.5M
96.7M shares
P/E
–
No P/E while losing money
Price to sales
49.5
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$89.0M
At Sep 30
Debt
$35.7M
At Sep 30
Shareholder equity
$38.4M
Shares outstanding
96.7M
At Nov 6
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $589K$589KFY2021FY2022: $39.9M$39.9MFY2022FY2023: $19.0M$19.0MFY2023FY2024: $11.0M$11.0MFY2024FY2025: $14.2M$14.2MFY2025

From IRD's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 10). Last 12 months adds up the four latest quarters.

Last report
Nov 10
2026 · next date not on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
Strong Buy
Based on 7 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Strong Buy
7firms
7 Buy0 Hold0 Sell
Each firm's latest rating on IRD in the past 90 days
Average 12-month target
$15.43
▲ 281.0% upside

Based on 7 analysts who set a price target on IRD in the past 90 days. The average target is $15.43, with a high of $20.00 and a low of $11.00, compared with the last close of $4.05.

Low $11.00Avg $15.43High $20.00
Blue marker: last close $4.05
Highest target$20.00
Average target$15.43
Lowest target$11.00
Latest rating changes
RBC CapitalTarget raised
Nov 11Buy$9 → $11
HC Wainwright & Co.Target raised
Nov 11Buy$8 → $14
Chardan CapitalMaintained
Oct 22Buy$16
CitizensTarget raised
Oct 16Buy$12 → $17
Jones TradingMaintained
Oct 6Buy$17
DateFirmActionRatingPrice target
Nov 11RBC CapitalTarget raisedBuy$9 → $11
Nov 11HC Wainwright & Co.Target raisedBuy$8 → $14
Oct 22Chardan CapitalMaintainedBuy$16
Oct 16CitizensTarget raisedBuy$12 → $17
Oct 6Jones TradingMaintainedBuy$17
Loading…

Technical Analysis

IRD · as of the Nov 17 close · updated after every close
Moving sideways

The stock sits between its 20 and 50 day averages. It is 6% below its 200 day average, so the longer trend is down. Momentum is improving (RSI 49). The nearest support is the Pivot at $4.01, and the nearest resistance the Pivot R1 at $4.11.

Short trendNeutral
Long trendBullish
MomentumImproving
StretchNormal
VolatilityNormal, 7.3%/day
Key levels
$7.0752 week high+74.6%
$4.4750 day average+10.4%
$4.28200 day average+5.7%
$4.22Swing high (Oct 21)+4.2%
$4.12100 day average+1.7%
$4.11Pivot R1+1.5%
$4.05Last close
$4.01Pivot−1.0%
$3.95Pivot S1−2.5%
$3.9120 day average−3.5%
$3.90Swing low (May 27)−3.7%
$1.7052 week low−58.0%
Indicators
RSI (14)49.03Middle of its rangeNeutral
MACD-0.03Above its signal lineBullish
Stochastic57.0Middle of its rangeNeutral
ADX (14)10.2No clear trend
Williams %R-42.7Oversold below −80, overbought above −20Neutral
CCI (20)31.6Oversold below −100, overbought above 100Neutral
Rate of change+3.0%Change over 10 sessionsBullish
ATR (14)$0.30Typical daily range, 7.3% of price
MA 10Below
MA 20Above
MA 50Below
MA 100Below
MA 200Below
What happened before, for IRD

What happened before

See how IRD did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Whale Options Flow

90D

No whale options trades in IRD in the last 90 days.

Loading…

See today’s whale options flow across the market →

IRD Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲77 buying vs 39 selling
  • ▲Held by funds +17.9 pts
  • ▲Funds holding +10
  • ▼Superinvestors: 1 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding113103+9.7%
In funds' top 10110.0%
Held by funds80.5%62.7%+17.9 pts
New / increased26 / 5139 / 32+8.5%
Reduced / sold out23 / 1612 / 16+39.3%
Put/call ratio0.00––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See IRD institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether IRD is in one of them and how their past IRD trades turned out.

IRD in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered IRD in an article yet. Here's the latest on the wider market.

About Opus Genetics

Opus Genetics is a biopharmaceutical company based in Durham, North Carolina. It is developing gene therapies meant to restore vision and prevent blindness in people with inherited retinal diseases, including Leber congenital amaurosis, bestrophinopathy and retinitis pigmentosa. The company is also developing a prescription eye solution for other ophthalmic conditions, and its target patients are people facing severe, often early-onset, eye disorders.

Headquarters
Durham, NC